Retatrutide vs Setmelanotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. It is investigational, made by Eli Lilly, and not yet FDA approved as of 2026.
Also: Imcivree, RM-493
Setmelanotide (brand name Imcivree) is a melanocortin-4 receptor (MC4R) agonist peptide and a genuine FDA-approved obesity drug, first cleared in 2020. It is not a general weight-loss shot like the GLP-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. It is given as a once-daily subcutaneous injection and has since been approved for additional conditions including Bardet-Biedl syndrome and acquired hypothalamic obesity.
Key Comparison Insights
- Setmelanotide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
Detailed Comparison
| Attribute | Retatrutide | Setmelanotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide combines three hormone signals into one molecule. The GLP-1 component curbs appetite and slows stomach emptying, the GIP component supports insulin response and may improve how fat tissue handles nutrients, and the added glucagon receptor activity is the novel piece: glucagon can increase energy expenditure and fat burning in the liver. The idea is that two arms cut how much you eat while the third raises how much you burn, which is why retatrutide is thought to push weight loss further than GLP-1-only drugs like semaglutide or even the dual GIP/GLP-1 agonist tirzepatide. The exact contribution of each receptor in humans is still being worked out, so consider the glucagon-driven energy-expenditure story a strong hypothesis rather than fully nailed down. | Deep in the hypothalamus there is a pathway that tells your brain you are full and that ramps up energy use. It runs through signals like leptin and POMC down to the MC4R receptor. In people with certain rare gene defects, such as POMC, PCSK1, or LEPR deficiency, that pathway is short-circuited upstream of MC4R, so the brain never gets the fullness signal and hunger is relentless. Setmelanotide bypasses the broken upstream step by binding and switching on MC4R directly, restoring the satiety and energy-expenditure signal. That is why it works specifically in these genetic and syndromic forms of obesity and would not be expected to fix common obesity the same way. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 2-3 mg daily Once daily |
| Administration | Subcutaneous injection weekly | Subcutaneous injection daily |
| Typical Duration | Long-term use expected | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human evidence is the phase 2 trial by Jastreboff and colleagues, published in the New England Journal of Medicine in 2023, which randomized 338 adults with obesity (without type 2 diabetes) over 48 weeks. Mean weight reduction reached about 24 percent at the 12 mg dose, and weight loss had not clearly plateaued by week 48, hinting the ceiling could be even higher. Among participants with prediabetes at baseline, a large majority returned to normal blood sugar. Side effects were dominated by gastrointestinal issues like nausea, vomiting, and diarrhea, the familiar pattern for this drug class, and were mostly dose-dependent. These are genuinely strong phase 2 results, but they are phase 2: larger and longer phase 3 trials are underway to confirm safety and durability, and retatrutide sold outside of trials is not an approved, quality-controlled medicine. | The human evidence is strong but deliberately narrow, matching the rare diseases it treats. The pivotal single-arm, open-label phase 3 trials in POMC and LEPR deficiency, published in The Lancet Diabetes and Endocrinology in 2020, reported that 80 percent of POMC patients and 45 percent of LEPR patients achieved at least 10 percent weight loss at about one year, alongside large drops in hunger scores. A separate randomized, placebo-controlled phase 3 trial supported approval in Bardet-Biedl syndrome, and a 2024 open-label trial (VENTURE) extended evidence to children as young as two. The trials were small because these conditions are extremely rare, so the data are best read as convincing within those specific genetic populations rather than as evidence for obesity broadly. The common side effects are consistent and manageable: skin hyperpigmentation, injection-site reactions, nausea, and headache, with no serious treatment-related events reported in the core trials. This is a legitimate approved drug for defined genetic indications, not an off-label general weight-loss peptide. |
Frequently Asked Questions: Retatrutide vs Setmelanotide
What is the difference between Retatrutide and Setmelanotide?
Retatrutide is a weight loss peptide that retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - gip, glp-1, and glucagon - earning it the nickname triple-g agonist. in a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. it is investigational, made by eli lilly, and not yet fda approved as of 2026. Setmelanotide is a weight loss peptide that setmelanotide (brand name imcivree) is a melanocortin-4 receptor (mc4r) agonist peptide and a genuine fda-approved obesity drug, first cleared in 2020. it is not a general weight-loss shot like the glp-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. it is given as a once-daily subcutaneous injection and has since been approved for additional conditions including bardet-biedl syndrome and acquired hypothalamic obesity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or Setmelanotide?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while Setmelanotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and Setmelanotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and Setmelanotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.